Kymera: T. Rowe Price reports 10.7% equity stake

Kymera Therapeutics, Inc. (KYMR) is the subject of an amended Schedule 13G filing in which T. Rowe Price Associates, Inc. reports beneficial ownership of 8,873,588 shares of common stock, representing 10.7% of the class as of August 31, 2026.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) is the subject of an amended Schedule 13G filing in which T. Rowe Price Associates, Inc. reports beneficial ownership of 8,873,588 shares of common stock, representing 10.7% of the class as of August 31, 2026.

T. Rowe Price Associates reports sole voting power over 8,821,580 shares and sole dispositive power over 8,873,588 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that the filing should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.

Key Figures

Shares beneficially owned: 8,873,588 shares Percent of class: 10.7% Sole voting power: 8,821,580 shares +3 more

6 metrics

Shares beneficially owned 8,873,588 shares Common stock of Kymera Therapeutics as reported by T. Rowe Price Associates

Percent of class 10.7% Portion of Kymera Therapeutics common stock class held by T. Rowe Price Associates

Sole voting power 8,821,580 shares Shares of Kymera Therapeutics common stock over which T. Rowe Price Associates has sole voting power

Shared voting power 0 shares Shares of Kymera Therapeutics common stock with shared voting power reported

Sole dispositive power 8,873,588 shares Shares of Kymera Therapeutics common stock over which T. Rowe Price Associates has sole dispositive power

Shared dispositive power 0 shares Shares of Kymera Therapeutics common stock with shared dispositive power reported

Key Terms

beneficial owner, Sole Voting Power, Sole Dispositive Power, Percent of class, +1 more

5 terms

beneficial owner regulatory

"shall not be construed as an admission that Price Associates is the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Sole Voting Power regulatory

"Sole Voting Power 8,821,580.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"Sole Dispositive Power 8,873,588.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Percent of class financial

"Percent of class: 10.7 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Schedule 13G regulatory

"T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What ownership stake in KYMR does T. Rowe Price Associates report in this Schedule 13G/A?

T. Rowe Price Associates reports beneficial ownership of 8,873,588 shares of Kymera Therapeutics common stock, representing 10.7% of the class as of August 31, 2026.

How much voting power over KYMR shares does T. Rowe Price Associates have?

T. Rowe Price Associates reports sole voting power over 8,821,580 shares of Kymera Therapeutics common stock and no shared voting power.

What dispositive power over KYMR shares is reported by T. Rowe Price Associates?

T. Rowe Price Associates reports sole dispositive power over 8,873,588 shares of Kymera Therapeutics common stock and no shared dispositive power.

Does T. Rowe Price Associates admit beneficial ownership of KYMR shares in this filing?

No. T. Rowe Price Associates states that the filing shall not be construed as an admission that it is the beneficial owner of the securities, and such beneficial ownership is expressly denied.

What type of securities of KYMR are covered in this Schedule 13G/A?

The filing covers common stock of Kymera Therapeutics, Inc., identified by CUSIP 501575104.

Where is Kymera Therapeutics, Inc. headquartered according to this filing?

Kymera Therapeutics, Inc. has its principal executive offices at 200 Arsenal Yards Blvd., Suite 230, Watertown, MA 02472.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 09:42 AM Accepted by SEC EDGAR 09/08/2026 - 09:42 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

KYMERA THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

501575104

(CUSIP Number)

08/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,821,580.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,873,588.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,873,588.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KYMERA THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN, MA, 02472
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 501575104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8873588
(b)	Percent of class: 10.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 8821580
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 8873588
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	09/08/2026